After over a decade spent building Incyte up into a competitive commercial drugmaker, the company’s longtime CEO Hervé ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...

While the first meeting of Robert F. Kennedy Jr.’s reshuffled Advisory Committee on Immunization Practices didn’t yield any ...

Saatchi & Saatchi Wellness announced Wednesday the appointments of three new leaders: Brendan Gallagher as president, Divya Dileep as chief creative officer and Beth Bour as the agency’s first-ever ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

In opening Wednesday’s meeting, newly appointed ACIP chair Martin Kulldorff, Ph.D., leaned into the controversy surrounding U ...

For many, inconsistent coding, patient finding challenges, and data silos mean those investments fail to translate into faster trials or better feasibility decisions. In this webinar, experts ...